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In recent years, the discovery of new active 
lipophilic molecules has been enormously 
increased.
However, major barriers facing the absorption 
of these lipophilic molecules following oral 
administration.
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Dahan and Hoffman, in Enhancement in Drug Delivery, CRC Press 2006
The barriers that a lipophilic molecule has to 
transverse along the intestinal absorption cascade 
In most cases, the solubilization in the intestinal 
milieu is the rate limiting step
Lipid based vehicle has been shown to enhance 
bioavailability of lipophilic drug.
Currently, the design of appropriate lipidic vehicles 
remains primarily empirical.
A dynamic in vitro model was proposed before that 
mimics the lipolysis process in the intestine 









System representative of fasted state intestinal 
environment, with maximum pseudo-physiological 
conditions
In vitro dynamic lipolysis model (stage 1)
In vitro dynamic lipolysis model (stage 2)
Drug in formulation is dispersed in the system
Experiment initiated with the insertion of pancreatic 
juice
Throughout lipolysis, free FA are released and pH is 
decreased and titrated immediately utilizing pH-stat 
titration unit and maintained at 7.0






















In vitro dynamic lipolysis model (stage 3)
Following the completion of the lipolysis, aliquots are taken 
from the system and ultracentrifuged:
Purpose
To investigate the IVIVC of the lipolysis 
model 
To assess the model as a predictive tool for the 
influences of different vehicles on the in-vivo 
oral absorption of lipophilic drugs
The advantages and limitations were 
investigated using 4 model drugs: progesterone, 
vitamin D3, dexamethasone and griseofulvin
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4 model lipophilic drugs:
Progesterone – undergoes presystemic
metabolism in the gut wall
Vitamin D3 – undergoes  lymphatic 
absorption
Dexamethasone – comparatively high water 
solubility (100 µg/ml)
Griseofulvin – practically insoluble in water
Log P = 4
Low oral bioavailability (less than 5%)
50% presystemic metabolism in the gut wall 
Progesterone
What is the effect of significant presystemic metabolism 
in the gut wall on the IVIVC of the lipolysis model?
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In vitro dynamic lipolysis model
Progesterone
Conclusion:
Performance rank order: MCT > LCT > SCT



















Aqueous phase Sediment Lipid phase




























Performance rank order: MCT > LCT > SCT
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In vitro - in vivo correlation (IVIVC)
Progesterone




Highly lipophilic, Log P = 9.1
Significant lymphatic absorption 
What is the effect of significant lymphatic absorption on 
the IVIVC of the lipolysis model?
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Dahan and Hoffman, Pharm Res 2006
Conclusion:


















Aqueous phase Sediment Lipid phase
In vitro dynamic lipolysis model
Vitamin D3
No IVIVC





























Performance rank order: LCT > MCT > SCT
In vivo oral bioavailability
Vitamin D3
9
Dahan and Hoffman, Eur J Pharm Sci 2005
Vitamin D3 plasma and lymph profiles




























































Dahan and Hoffman, Eur J Pharm Sci 2005
Pretreatment with cycloheximide eliminates the lymphatic 
transport, without affecting other absorption pathways
Cycloheximide
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Dahan and Hoffman, Pharm Res 2006
In vivo oral bioavailability of Vitamin D3 
in cycloheximide treated animals
Conclusion:
























The in-vitro lipolysis model managed to predict the 
performance of different lipidic vehicles in-vivo
Presystemic metabolism in the gut wall did not influence 
this IVIVC
Lymphatic absorption of the drug may interfere with this 
IVIVC, since LCT oil is necessary for chylomicron 
production
The potential of a lipophilic drug to undergo lymphatic 
absorption has to be examined (see poster PS-04)
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The correlation between in-vitro lipolysis, 
intestinal permeability and in vivo absorption
Lipid based formulation has direct influence on the 
permeation of the drug through the gut wall
To assess the IVIVC of the lipolysis model in light of the 
influence of different vehicles on the intestinal 
permeability
2 Model Drugs sharing the same Log P (~2) but differ in 
their water solubility characteristics: 
Dexamethasone - Relatively good water solubility
Griseofulvin - Practically insoluble in water
Dexamethasone
Log P = 2
Relatively good water solubility (100 µg/ml)
What is the effect of gut wall permeation abilities on the 
IVIVC of the lipolysis model?
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In vitro dynamic lipolysis model
Dexamethasone
Conclusion:




















Aqueous phase Sediment phase Lipid phase
Conclusion:
Performance rank order: SCT > MCT ≥ LCT
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Performance rank order: MCT = LCT = SCT
IVIVC with lipolysis and not with permeation




























Log P = 2
Practically insoluble in water
What is the effect of gut wall permeation abilities on the 




















Aqueous phase Sediment phase Lipid phase
In vitro dynamic lipolysis model
Griseofulvin
Conclusion:
Performance rank order: MCT>LCT>SCT>H2O
Ex vivo intestinal permeation model
Griseofulvin
Conclusion:
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In vivo oral bioavailability
Griseofulvin
Conclusion:
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In vitro - in vivo correlation (IVIVC)
Griseofulvin
Conclusion:
Good IVIVC (R2>0.98) with the lipolysis model
No correlation with the permeation studies
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The in-vitro lipolysis model managed to 
predict the performance of different lipidic 
vehicles in-vivo
Valuable information can be obtained from 
the in-vitro lipolysis model, leading to the 
intelligent selection of lipidic vehicles
Conclusions (1) 
For class 2 drugs, permeation studies may not predict 
actual in-vivo performance
The influence of the vehicle on the permeability does not 
affect in-vivo bioavailability of class 2 drugs, hence does 
not damage the prediction of the lipolysis model
SCT vehicle shown to be a potential intestinal 
permeability enhancer
The differences between solubilization abilities of the 





Significant presystemic metabolism in the gut wall 
does not affect the ability of the model to predict 
in-vivo performance
For drugs that undergo lymphatic absorption the 
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